Methotrexate oral or subcutaneous for rheumatoid arthritis (MOOSE): study protocol for a multi-centre randomised trial
(2025)
Journal Article
McClure, S., Haydock, R., Su, Y., Rick, C., Blackburn, S., Brooks, M., Edwards, C. J., Mallen, C., Raza, K., Jinks, C., Stevenson, M., Montgomery, A., Hepburn, T., & Abhishek, A. (2025). Methotrexate oral or subcutaneous for rheumatoid arthritis (MOOSE): study protocol for a multi-centre randomised trial. Trials, 26(1), 495. https://doi.org/10.1186/s13063-025-09020-4
Background: Rheumatoid arthritis is the commonest chronic inflammatory arthritis. Oral methotrexate is recommended as the first-line disease modifying drug for its management, and subcutaneous injections are typically prescribed if there is gastroint... Read More about Methotrexate oral or subcutaneous for rheumatoid arthritis (MOOSE): study protocol for a multi-centre randomised trial.